Laekna Inc
Company Profile
Business description
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated one clinical trial and another five clinical trials for its Core Products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers. Laekna has two Core Products and 14 other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors.
Contact
No. 3-2-467, 5 Xingbin Road (Lin Li Center)
Sino-Italy Ningbo Ecological Park
Zhejiang Province
Yuyao201203
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
84
Stocks News & Analysis
stocks
US utilities stocks keep rallying as investors bet on power demand growth
stocks
What did Morningstar subscribers buy and sell during March?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.00 | 41.40 | -0.45% |
| CAC 40 | 8,235.98 | 23.62 | -0.29% |
| DAX 40 | 23,742.44 | 61.51 | -0.26% |
| Dow JONES (US) | 48,218.25 | 301.68 | 0.63% |
| FTSE 100 | 10,582.96 | 17.57 | -0.17% |
| HKSE | 25,770.40 | 109.55 | 0.43% |
| NASDAQ | 23,183.74 | 280.84 | 1.23% |
| Nikkei 225 | 57,910.16 | 1,407.39 | 2.49% |
| NZX 50 Index | 13,000.60 | 19.58 | -0.15% |
| S&P 500 | 6,886.24 | 69.35 | 1.02% |
| S&P/ASX 200 | 8,969.60 | 44.40 | -0.49% |
| SSE Composite Index | 4,010.45 | 21.89 | 0.55% |